Cytogenomic Profile of Uterine Leiomyoma: In Vivo vs. In Vitro Comparison
暂无分享,去创建一个
T. Liehr | V. Baranov | O. Malysheva | O. Chiryaeva | I. Kogan | Ahmed Al-Rikabi | M. Yarmolinskaya | A. S. Koltsova | A. Glotov | O. Bespalova | G. Tolibova | T. Tral | O. Efimova | N. Osinovskaya | I. Y. Sultanov | A. Pendina | N. Shved | M. I. Kakhiani | Nikolai I. Polenov | Vladislava V. Kunitsa
[1] C. Simón,et al. Molecular and Cellular Insights into the Development of Uterine Fibroids , 2021, International journal of molecular sciences.
[2] V. Baranov,et al. Telomere Length in Chromosomally Normal and Abnormal Miscarriages and Ongoing Pregnancies and Its Association with 5-hydroxymethylcytosine Patterns , 2021, International journal of molecular sciences.
[3] V. Baranov,et al. Telomere Length in Metaphase Chromosomes of Human Triploid Zygotes , 2021, International journal of molecular sciences.
[4] Dong Zhang,et al. ALT Positivity in Human Cancers: Prevalence and Clinical Insights , 2021, Cancers.
[5] V. Baranov,et al. Uterine Leiomyomas with an Apparently Normal Karyotype Comprise Minor Heteroploid Subpopulations Differently Represented in vivo and in vitro , 2021, Cytogenetic and Genome Research.
[6] F. Chibon,et al. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond , 2020, Genes, chromosomes & cancer.
[7] P. Campbell,et al. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis , 2020, Nature Genetics.
[8] O. A. Efimova,et al. Environmental Epigenetics and Genome Flexibility: Focus on 5-Hydroxymethylcytosine , 2020, International journal of molecular sciences.
[9] S. As-Sanie,et al. Epidemiology and management of uterine fibroids , 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[10] D. Baird,et al. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African-Americans. , 2020, American journal of obstetrics and gynecology.
[11] V. Baranov,et al. Pathogenomics of Uterine Fibroids Development , 2019, International journal of molecular sciences.
[12] A. Ciavattini,et al. Comparison of uterine fibroids’ growth pattern during pregnancy according to fetal sex: an observational study , 2019, Biology of Sex Differences.
[13] A. Shushan,et al. Growth pattern of uterine leiomyoma along pregnancy , 2019, BMC Women's Health.
[14] Jinhui Xu,et al. Chromosome territories and the global regulation of the genome , 2019, Genes, chromosomes & cancer.
[15] E. Hendrickson,et al. Chromothripsis during telomere crisis is independent of NHEJ, and consistent with a replicative origin , 2019, Genome research.
[16] T. Hernández-Beeftink,et al. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas. , 2018, Gynecologic oncology.
[17] J. Segars,et al. The Effect of Uterine Fibroids on Infertility: A Systematic Review , 2017, Seminars in Reproductive Medicine.
[18] V. Baranov,et al. Case of chromothripsis in a large solitary non-recurrent uterine leiomyoma. , 2017, European journal of obstetrics, gynecology, and reproductive biology.
[19] V. Baranov,et al. Differential DNA Hydroxymethylation in Human Uterine Leiomyoma Cells Depending on the Phase of Menstrual Cycle and Presence of MED12 Gene Mutations , 2017, Bulletin of Experimental Biology and Medicine.
[20] E. Stewart,et al. Epidemiology of uterine fibroids: a systematic review , 2017, BJOG : an international journal of obstetrics and gynaecology.
[21] P. Vahteristo,et al. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors , 2017, Molecular Cancer.
[22] T. Lange,et al. Telomeres in cancer: tumour suppression and genome instability , 2017, Nature Reviews Molecular Cell Biology.
[23] V. Baranov,et al. Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[24] V. Baranov,et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with increased risk of multiple uterine leiomyomas either positive or negative for MED12 exon 2 mutations , 2016, Journal of Clinical Pathology.
[25] J. Geigl,et al. Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors , 2016, Modern Pathology.
[26] F. Parazzini,et al. Pregnancy outcome and uterine fibroids. , 2016, Best practice & research. Clinical obstetrics & gynaecology.
[27] L. Aaltonen,et al. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas , 2016, British Journal of Cancer.
[28] Qiwei Yang,et al. Early Life Adverse Environmental Exposures Increase the Risk of Uterine Fibroid Development: Role of Epigenetic Regulation , 2016, Front. Pharmacol..
[29] L. Wise,et al. Epidemiology of Uterine Fibroids: From Menarche to Menopause. , 2016, Clinical obstetrics and gynecology.
[30] V. Baranov,et al. Comparative systems genetics view of endometriosis and uterine leiomyoma: Two sides of the same coin? , 2016, Systems biology in reproductive medicine.
[31] L. Aaltonen,et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers , 2016, Proceedings of the National Academy of Sciences.
[32] J. Bullerdiek,et al. A rare coincidence of different types of driver mutations among uterine leiomyomas (UL) , 2015, Molecular Cytogenetics.
[33] R. Moon,et al. Wnt signaling induces transcription, spatial proximity, and translocation of fusion gene partners in human hematopoietic cells. , 2015, Blood.
[34] Suman Lee,et al. Epigenetic instability of imprinted genes in human cancers , 2015, Nucleic acids research.
[35] J. Teixeira,et al. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. , 2015, Human reproduction update.
[36] P. Yin,et al. Uterine Leiomyoma Stem Cells: Linking Progesterone to Growth , 2015, Seminars in Reproductive Medicine.
[37] F. Guyon,et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions , 2015, Modern Pathology.
[38] Esa Pitkänen,et al. Clonally related uterine leiomyomas are common and display branched tumor evolution. , 2015, Human molecular genetics.
[39] J. Bullerdiek,et al. Cytogenetically normal uterine leiomyomas without MED12-mutations – a source to identify unknown mechanisms of the development of uterine smooth muscle tumors , 2014, Molecular Cytogenetics.
[40] Diana Magalhaes de Oliveira,et al. The linked human imprintome v1.0: over 120 genes confirmed as imprinted impose a major review on previous censuses , 2014, Int. J. Data Min. Bioinform..
[41] A. Clayton,et al. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. , 2014, American journal of obstetrics and gynecology.
[42] Yunlang Cai,et al. Measurement of Phenolic Environmental Estrogens in Women with Uterine Leiomyoma , 2013, PloS one.
[43] Cameron S. Osborne,et al. Molecular Pathways Molecular Pathways : Transcription Factories and Chromosomal Translocations , 2013 .
[44] L. Aaltonen,et al. Characterization of uterine leiomyomas by whole-genome sequencing. , 2013, The New England journal of medicine.
[45] D. Baird,et al. Gene Expression in Uterine Leiomyoma from Tumors Likely to Be Growing (from Black Women over 35) and Tumors Likely to Be Non-Growing (from White Women over 35) , 2013, PloS one.
[46] T. Löning,et al. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups , 2012, International journal of cancer.
[47] J. Harizanova,et al. Differential positioning and close spatial proximity of translocation‐prone genes in nonmalignant B‐cells from multiple myeloma patients , 2012, Genes, chromosomes & cancer.
[48] Tae-Min Kim,et al. Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12;14) and evidence in support of predisposing genetic heterogeneity. , 2012, Human molecular genetics.
[49] C. Walker,et al. Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis , 2012, Molecular Cancer Research.
[50] Fuqiang Huang,et al. Hypoxia: the driving force of uterine myometrial stem cells differentiation into leiomyoma cells. , 2011, Medical hypotheses.
[51] L. Campbell,et al. The Role of Dicentric Chromosome Formation and Secondary Centromere Deletion in the Evolution of Myeloid Malignancy , 2011, Genetics research international.
[52] D. Baird,et al. Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array. , 2011, Experimental and molecular pathology.
[53] P. Park,et al. Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis , 2009, Genes, chromosomes & cancer.
[54] J. Bullerdiek,et al. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease , 2009, Genes, chromosomes & cancer.
[55] Y. Cho,et al. Array comparative genomic hybridization analysis of uterine leiomyosarcoma. , 2005, Gynecologic oncology.
[56] A. Sandberg. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. , 2005, Cancer genetics and cytogenetics.
[57] P. Vercellini,et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. , 2003, Fertility and sterility.
[58] S. Weremowicz,et al. HMGA2 expression in uterine leiomyomata and myometrium: Quantitative analysis and tissue culture studies , 2003, Genes, chromosomes & cancer.
[59] Tom Misteli,et al. Spatial proximity of translocation-prone gene loci in human lymphomas , 2003, Nature Genetics.
[60] J. Haseman,et al. Immortalization of Human Uterine Leiomyoma and Myometrial Cell Lines After Induction of Telomerase Activity: Molecular and Phenotypic Characteristics , 2002, Laboratory Investigation.
[61] R. Fuchs-Young,et al. An in vivo/in vitro Model to Assess Endocrine Disrupting Activity of Xenoestrogens in Uterine Leiomyoma , 2001, Annals of the New York Academy of Sciences.
[62] M. Sakamoto,et al. Telomerase activity in gynecological tumors. , 2000, Oncology reports.
[63] K. Hirschhorn,et al. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. , 2000, Cancer genetics and cytogenetics.
[64] C. Morton,et al. Genetics of uterine leiomyomata , 2000, Bulletin du cancer.
[65] L. Giudice,et al. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium , 2000, International journal of cancer.
[66] W. Jonat,et al. Telomere shortening in uterine leiomyomas. , 1998, American journal of obstetrics and gynecology.
[67] C. Morton,et al. The del(7q) subgroup in uterine leiomyomata: genetic and biologic characteristics. Further evidence for the secondary nature of cytogenetic abnormalities in the pathobiology of uterine leiomyomata. , 1997, Cancer genetics and cytogenetics.
[68] A. Berchuck,et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization , 1997, Molecular carcinogenesis.
[69] S. Scherer,et al. Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas , 1997, Oncogene.
[70] P. Cin,et al. Molecular cytogenetic characterization of del(7q) in two uterine leiomyoma‐derived cell lines , 1997, Genes, chromosomes & cancer.
[71] J. Deprest,et al. Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females. , 1996, Fertility and sterility.
[72] K. Ohama,et al. Detection of chromosomal abnormalities in uterine leiomyoma using conventional cytogenetic method and interphase fluorescence in situ hybridization. , 1996, Cancer genetics and cytogenetics.
[73] K. Ohama,et al. Detection of chromosomal abnormalities of chromosome 12 in uterine leiomyoma using fluorescence in situ hybridization , 1996, Japanese Journal of Human Genetics.
[74] U. Surti,et al. Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas , 1995, Genes, chromosomes & cancer.
[75] J. Sklar,et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata , 1994, Genes, chromosomes & cancer.
[76] L. Meisner,et al. Comparison of chromosome aberrations in leiomyoma and leiomyosarcoma using FISH on archival tissues. , 1994, Cancer genetics and cytogenetics.
[77] U. Surti,et al. Deletion 7q22 in uterine leiomyoma. A cytogenetic review. , 1993, Cancer genetics and cytogenetics.
[78] U. Surti,et al. Chromosome 7 biclonality in uterine leiomyoma. , 1993, Cancer genetics and cytogenetics.
[79] F. Speleman,et al. Uterine leiomyoma cytogenetics. III. Interphase cytogenetic analysis of karyotypically normal uterine leiomyoma excludes possibility of undetected trisomy 12. , 1992, Cancer genetics and cytogenetics.
[80] U. Surti,et al. Subgroups of uterine leiomyomas based on cytogenetic analysis. , 1991, Human pathology.
[81] F. Mitelman,et al. Chromosome analysis of 96 uterine leiomyomas. , 1991, Cancer genetics and cytogenetics.
[82] J. Fletcher,et al. Cytogenetic Abnormalities in Uterine Leiomyomata , 1991, Obstetrics and gynecology.
[83] F. Mitelman,et al. Parallel karyotypic evolution and tumor progression in uterine leiomyoma , 1990, Genes, chromosomes & cancer.
[84] J. Fletcher,et al. Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability. , 1990, Cancer research.
[85] S. Heim,et al. Uterine leiomyoma cytogenetics , 1990, Genes, chromosomes & cancer.
[86] I. Konishi,et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. , 1989, American journal of obstetrics and gynecology.
[87] S. Gartler,et al. Glucose-6-Phosphate Dehydrogenase Mosaicism: Utilization as a Cell Marker in the Study of Leiomyomas , 1965, Science.
[88] T. Liehr. Fluorescence In Situ Hybridization (FISH) , 2017, Springer Protocols Handbooks.
[89] V. Baranov,et al. Immunofluorescence Staining for Cytosine Modifications Like 5-Methylcytosine and Its Oxidative Derivatives and FISH , 2017 .
[90] David B Dunson,et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. , 2003, American journal of obstetrics and gynecology.
[91] C. Walker. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. , 2002, Recent progress in hormone research.
[92] F. Mitelman,et al. Karyotypic rearrangements in 20 uterine leiomyomas. , 1988, Cytogenetics and cell genetics.
[93] P. Vahteristo,et al. Characterization of MED 12 , HMGA 2 , and FH alterations reveals molecular variability in uterine smooth muscle tumors , 2022 .